METHODS FOR INDUCING INTERLEUKIN-12 AND A TYPE1/TH1 T-CELL RESPONSE IN DERMATOLOGIC DISEASE
UCLA Technology Available For Licensing

UCLA investigators have identified a use for bacterial lipopeptides as a potent inducer of IL-12 production and resulting type 1/Th-1 T-cell response. The technology encompasses a broad range of lipoproteins of defined structure that can be administered to a subject to trigger type 1/Th1 T cell response required for cell-mediated immunity in the context of infection, autoimmune disease or cancer.

For example, and of current interest, the lipoprotein may be used as a topical agent for the treatment of skin infections and cancer, in which Th1 responses are required for host defense. Since this lipoprotein activates Toll-like receptor 2, it has a novel mechanism of action.

Reference: UCLA Case No. 1997-505 US Patent Number: 6,517,839

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
Lead Inventor: Robert Modlin

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/tech

Copyright © 2001 The Regents of the University of California.

keywords: therapeutics uclancd ucla technologies intellectual property patents technology transfer invention business card